Helixgate

Helixgate

Uncategorized

Clot-busting drug could harm stroke treatment response 

Published

on

A laboratory mouse

A clot-busting drug may stop promising stroke medicine from working properly, research reveals. 

Researchers at the University of Manchester found the clot-busting therapy, known as tissue plasminogen activator (tPA), interacts negatively with the anti-inflammatory treatment anakinra, highlighting the need for new stroke therapies alongside existing standard care. 

Results from the study on mice, published in the American Heart Association Stroke journal, show the timing of anakinra delivery must be adjusted to avoid reducing the benefits of tPA. 

Anakinra, an interleukin1 receptor antagonist (IL-1Ra), blocks IL1 and has shown promise in reducing inflammation in both laboratory and early clinical studies of stroke. 

“Our findings suggest that IL-1Ra can interfere with tPA’s ability to dissolve clots when the two drugs are present in the bloodstream at the same time,” said Dr Ioana-Emilia Mosneag, lead author on the study. 

“The results also help explain why IL-1Ra levels were lower in patients who received tPA first, as plasmin generated during clot-busting appears to break down IL-1Ra.  

“However, the effect of tPA on IL-1Ra – the opposite order – isn’t necessarily a problem as IL-1RA was still active in reducing IL-6 in the SCIL-STROKE study, but this needs further evaluation.” 

Trial results ‘raise questions’ about drug interaction

Stroke is the second leading cause of death and disability worldwide, as experts estimate the number of people affected could rise by more than 80% over the next 25 years. 

Despite decades of research and thousands of experimental drugs, the only approved medicines for treating the most common type of stroke, ischaemic stroke, are clot-busting drugs known as plasminogen activators, like tPA. 

Though tPA can be lifesaving for acute ischaemic stroke, about 2–6% of treated patients develop potentially fatal brain bleeding, according to the ECASS III trial of the early 2000s. 

Scientists now know that inflammation plays a major role in worsening brain injury after a stroke, mostly driven by a molecule called interleukin1 (IL1). The IL-1RA anakinra is a therapy used to reduce inflammation. 

However, a Phase II clinical trial (SCILSTROKE) found that IL1Ra did not improve patient recovery overall. 

“The findings of SCILSTROKE raise questions about whether the drug might interact negatively with standard clotbusting treatment,” said Mosneag. 

Wirth nearly three quarters of patients in the SCILSTROKE trial receiving the clotbusting drug tPA before IL-1Ra, researchers set out to investigate whether the two treatments might negatively interact with each other. 

They re-examined data from the SCILSTROKE trial and discovered that patients who received tPA before IL-1Ra had significantly lower levels of IL-1Ra in their blood, suggesting the drug was being broken down. 

Laboratory research confirmed that IL-1Ra can be cut apart by plasmin, an enzyme produced during tPA treatment, meaning the anti-inflammatory drug may be degraded before it can work. 

Timing of drug delivery ‘very likely to be a critical factor’

Following results from the SCILSTROOKE trial, researchers tested drug interaction in a mouse model of stroke, using dosing schedules that matched those used in the clinical trial. 

When IL-1Ra was given after tPA, no harmful interaction was seen and the protective effects of tPA were preserved. 

However, when IL-1Ra was given at the same time as tPA — during the clot-busting process — the benefits of tPA were dramatically reduced, with brain damage shrinking by only 15% compared to 68% with tPA alone. 

The mice receiving both drugs together also showed poorer blood flow in the brain, more inflammatory immune cells entering damaged tissue, and higher levels of harmful structures called neutrophil extracellular traps. This indicates that the drug interaction is also detrimental to the anti-inflammatory effect of IL-1Ra. 

“This study shows that timing is very likely to be a critical factor in the efficacy of IL-1Ra, which will be beneficial if given after tPA rather than alongside it,” said Professor Stuart Allan, co-author on the study. 

“We also need to test whether similar interactions occur with other clot-busting drugs such as tenecteplase, which may be less likely to break down IL-1Ra due to its greater specificity.” 

 

 

 

 

 

 

 

The post Clot-busting drug could harm stroke treatment response  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

on

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

 

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading
Advertisement

Trending